Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Chongqing Medical University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07645157CT.gov Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression | — | Recruiting | — | — | — |
NCT07539805CT.gov Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression | — | Recruiting | — | — | — |
NCT07139834CT.gov Pattern Separation in Major Depressive Disorder | — | Not Yet Recruiting | — | — | — |
NCT06384209CT.gov The Friendship Bench Plus Trial | — | Recruiting | — | — | — |
NCT07011693CT.gov Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I) | — | Not Yet Recruiting | — | — | — |
NCT05603104CT.gov Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | — | Recruiting | — | — | — |
NCT06965569CT.gov Multiple Ascending Dose Phase 1 Study of ALA-3000 | — | Completed | — | — | — |
NCT06827431CT.gov The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | — | Not Yet Recruiting | — | — | — |
NCT05554627CT.gov VA Aripiprazole vs Esketamine for Treatment Resistant Depression | — | Withdrawn | — | — | — |
NCT05892744CT.gov Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression | — | Recruiting | — | — | — |
Show 76 more trialsShow fewer
NCT05930912CT.gov Psychiatric Orders in Psychoanalytic Treatment of ASD | — | Unknown | — | — | — |
NCT06698666CT.gov Efficacy of Statins Among Major Depressive Disorder | — | Recruiting | — | — | — |
NCT05537584CT.gov SMART Trial to Predict Anhedonia Response to Antidepressant Treatment | — | Completed | — | — | — |
NCT04446039CT.gov Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea | — | Completed | — | — | — |
NCT05950061CT.gov Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder | — | Completed | — | — | — |
NCT05273996CT.gov Predictors of Cognitive Outcomes in Geriatric Depression | — | Active Not Recruiting | — | — | — |
NCT04476030CT.gov A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT04388202CT.gov Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram | — | Withdrawn | — | — | — |
NCT05210153CT.gov Personalized Sertraline Dosing in Patients With Depression | — | Withdrawn | — | — | — |
NCT04171193CT.gov Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent | — | Unknown | — | — | — |
NCT04183205CT.gov Predicting SSRI Efficacy in Veterans With PTSD | — | Terminated | — | — | — |
NCT03779789CT.gov Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment | — | Completed | — | — | — |
NCT03790085CT.gov Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals | — | Unknown | — | — | — |
NCT04430556CT.gov Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients | — | Unknown | — | — | — |
NCT04637620CT.gov NMDA Modulation in Major Depressive Disorder | — | Recruiting | — | — | — |
NCT02977299CT.gov Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD | — | Completed | — | — | — |
NCT03514810CT.gov Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder | — | Completed | — | — | — |
NCT02752542CT.gov Personalized Indications for CBT and Antidepressants in Treating Depression | — | Recruiting | — | — | — |
NCT03414931CT.gov NMDA Modulation in Major Depressive Disorder in Late- Life | — | Completed | — | — | — |
NCT02497287CT.gov A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | — | Completed | — | — | — |
NCT02417064CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02418585CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02269540CT.gov A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A) | — | Completed | — | — | — |
NCT02268487CT.gov Integral Assessment in Unipolar Depression | — | Unknown | — | — | — |
NCT01942187CT.gov A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults | — | Withdrawn | — | — | — |
NCT01896934CT.gov Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression | — | Completed | — | — | — |
NCT01896349CT.gov Interpersonal Psychotherapy for Treatment Resistant Depression | — | Unknown | — | — | — |
NCT01703039CT.gov Riluzole Augmentation Pilot in Depression (RAPID) Trial | — | Terminated | — | — | — |
NCT01856127CT.gov Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction? | — | Terminated | — | — | — |
NCT01764867CT.gov Algorithm Guided Treatment Strategies for Major Depressive Disorder | — | Unknown | — | — | — |
NCT01655706CT.gov Canadian Biomarker Integration Network for Depression Study | — | Completed | — | — | — |
NCT01488266CT.gov Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder | — | Unknown | — | — | — |
NCT01436162CT.gov Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01360866CT.gov Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | — | Completed | — | — | — |
NCT02473783CT.gov The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD | — | Completed | — | — | — |
NCT02237937CT.gov Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene | — | Unknown | — | — | — |
NCT01429831CT.gov Aripiprazole for the Augmentation of Antidepressant Therapy | — | Completed | — | — | — |
NCT01435759CT.gov SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01254305CT.gov Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder | — | Completed | — | — | — |
NCT01305889CT.gov The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders | — | Completed | — | — | — |
NCT01109693CT.gov Strategic Use of New Generation Antidepressants for Depression | — | Completed | — | — | — |
NCT01123707CT.gov To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01250873CT.gov A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline | — | Completed | — | — | — |
NCT01111565CT.gov Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01111552CT.gov Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01111539CT.gov Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT01033084CT.gov Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder | — | Completed | — | — | — |
NCT00905424CT.gov Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant | — | Completed | — | — | — |
NCT00854100CT.gov Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder | — | Completed | — | — | — |
NCT00953745CT.gov Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression | — | Completed | — | — | — |
NCT01027559CT.gov fMRI Study of Treatment Changes in Major Depression | — | Completed | — | — | — |
NCT00693849CT.gov International Study to Predict Optimised Treatment - in Depression | — | Unknown | — | — | — |
NCT01454635CT.gov Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder | — | Completed | — | — | — |
NCT00421369CT.gov Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. | — | Completed | — | — | — |
NCT00873795CT.gov Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression | — | Completed | — | — | — |
NCT00406952CT.gov Study for Evaluating Different Methods of Measuring Depression Treatment Response | — | Completed | — | — | — |
NCT00351910CT.gov Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT00275197CT.gov A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD) | — | Completed | — | — | — |
NCT00608543CT.gov Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression | — | Completed | — | — | — |
NCT00143091CT.gov Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder | — | Terminated | — | — | — |
NCT00220636CT.gov Abilify as an Adjunctive Treatment for Refractory Depression | — | Completed | — | — | — |
NCT00208169CT.gov Abilify Therapy for Reducing Comorbid Substance Abuse | — | Completed | — | — | — |
NCT00245557CT.gov Magnetic Resonance Imaging Study of Geriatric Depression | — | Completed | — | — | — |
NCT00179257CT.gov The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram | — | Completed | — | — | — |
NCT00636246CT.gov A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression. | — | Completed | — | — | — |
NCT00229476CT.gov Study of Medication and Placebo Response in Major Depression | — | Completed | — | — | — |
NCT00056472CT.gov Study of Pharmacotherapy of Psychotic Depression | — | Completed | — | — | — |
NCT00158990CT.gov Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. | — | Completed | — | — | — |
NCT00644982CT.gov A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression | — | Completed | — | — | — |
NCT00182533CT.gov Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders | — | Terminated | — | — | — |
NCT00179283CT.gov Sertraline vs. Venlafaxine XR | — | Completed | — | — | — |
NCT00177996CT.gov Pharmacotherapy in Depression With Panic Spectrum | — | Completed | — | — | — |
NCT00581009CT.gov The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients | — | Completed | — | — | — |
NCT00005013CT.gov Treatment of Major Depression With St. John's Wort (Hypericum) | — | Completed | — | — | — |
NCT00374426CT.gov Preventing Depression Recurrence in Diabetes | — | Completed | — | — | — |
NCT00208702CT.gov Thyroid Medication and Antidepressants for Treating Major Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sertraline (this asset) | First Affiliated Hospital of Chongqing Medical University | Approved | BB · 71 |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Desvenlafaxine | Pfizer | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Sertraline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anxiety Disorder | — | P4 | BBB · 76 |
| Psychotic Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sertraline in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sertraline-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →